Cardiometabolic
Europe Is Moving to Ban Red Yeast Rice Monacolins. Can Bergamot Fill the Gap?
EU scrutiny of red yeast rice monacolins is accelerating a shift in the cholesterol supplement market toward botanical alternatives, including bergamot-based formulations. A clinically studied bergamot phytocomplex has shown improvements in lipid and metabolic markers in a small randomised trial, but evidence of cardiovascular protection remains absent.
Coffee drinkers had less visceral fat despite similar BMI. The finding exposes what the scale misses
Avexitide Phase 3 trial cuts post-bariatric hypoglycemia events by 55%
A sweat patch can continuously track cholesterol and triglycerides. Blood tests are not obsolete yet
The first oral PCSK9 inhibitor is approved. A pill will not fix cholesterol access by itself
Oral GLP-1 drugs could widen access, but high prices may do the opposite
GLP-1 drugs can reduce adolescent obesity. Who will pay for years of treatment?
Boehringer Ingelheim is adding a third target to obesity treatment.
The weight came back. Some visceral fat did not. Obesity care may be measuring the wrong outcome
The ovaries were never the whole story: PMOS linked to heart attacks and strokes in more than two million women
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
Diseases in Cardiometabolic
Explore disease data and country profiles on the IPM Alliance platform.
Explore diseases